Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
115180.KQ
STRONG SELLQurient Co., Ltd. · Healthcare · South Korea · $614M · Avg Vol: $2M/d
2
StockRankQ
23
V
20
M
26
P/E (TTM)
—
ROE
-75.5%
D/E
0.4x
Dividend %
—
COMPANY DESCRIPTION
Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | 5.6M | 5.9M | 6.0M | 4.6M | -6.2% |
| EPS | -0.45 | -1.02 | -0.53 | -0.58 | — |
| Shares | 37.3M | 26.6M | 32.3M | 37.2M | -0.2% |
| Debt | 0.5M | 0.2M | 0.6M | 8.3M | 150.2% |
| Equity | 20.4M | 28.9M | 33.0M | 22.4M | 3.2% |
| Op CF | -16.5M | -14.5M | -15.3M | -18.9M | — |
| Inv CF | 13.9M | 2.7M | -15.9M | -5.6M | — |
| Fin CF | 4.1M | 20.8M | 17.6M | 27.9M | — |
Loading...
PRICE (1Y)-29.9%
SMA 50SMA 200
Close
$14.68
RSI (14)
35.3
52W High
$41.40
From 52W High
0.4%
SCORE BREAKDOWN
Quality
23
ROIC
-53.3%12.8
ROE
-75.5%10.8
GP/Assets
1.4%13.2
Op. Margin
-394.8%10.8
FCF/Assets
-35.0%7.0
Piotroski
25.5
Int. Cover
-50.0x6.0
D/E Ratio
0.40x37.0
Current Ratio
19.26x95.1
Value
20
P/E (TTM)
—N/A
EV/EBITDA
-32.2x25.0
P/FCF
—N/A
P/B
28.7x3.4
P/S
134.1x6.5
Div Yield
—N/A
Momentum
26
52W High %
35%9.2
RS 6M
-145%4.7
SMA 50/200
1.12x82.5
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$614M
P/E (Forward)
—
Gross Margin
12.5%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 115180.KQ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 115180.KQ | Qurient Co., Ltd.(you) | $614M | 2 | STRONG SELL |
| 456160.KQ | G2GBIO | $514M | 3 | STRONG SELL |
| 048410.KQ | Hyundai Bioscience Co., Ltd. | $578M | 7 | STRONG SELL |
| 174900.KQ | AbClon Inc. | $477M | 4 | STRONG SELL |
| 085660.KQ | Chabiotech Co.,Ltd. | $595M | 10 | STRONG SELL |
| 397030.KQ | AprilBio Co.,Ltd. | $621M | 10 | STRONG SELL |
| 475830.KQ | Orum Therapeutics, Inc. | $865M | 4 | STRONG SELL |
| 476830.KQ | Rznomics | $846M | 8 | STRONG SELL |
| 005690.KS | Pharmicell Co., Ltd. | $598M | 14 | STRONG SELL |
| 127120.KQ | JS Link, Inc. | $779M | 14 | STRONG SELL |
Peer medians: ROE -1.1% · P/E 17.7x · Gross margin 43.6%